Clinical Trials
19 trialsNCT06897735 2026-06-03
EDDIS-a1
Petrov, Andrey
Phase 1 Terminated
NCT06302621 2026-05-15
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
Phase 1 Recruiting
NCT01783587 2026-03-25
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06494189 2025-12-29
Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma
West China Hospital
Phase 1 Completed
NCT06741982 2024-12-19
A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV Virus
West China Hospital
Phase 1 Recruiting
NCT02364609 2024-10-16
Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib
University of California, Davis
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03711422 2022-06-14
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC
National Cancer Centre, Singapore
Phase 1 Terminated
NCT02451553 2022-06-07
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
Phase 1 Completed
NCT03054038 2022-04-14
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Terminated
NCT02423525 2022-03-10
Safety Study of Afatinib for Brain Cancer
Saint John's Cancer Institute
Phase 1 Completed
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01679405 2019-09-06
BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer
Johannes Gutenberg University Mainz
Phase 1 Terminated
NCT03652233 2019-06-20
Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT02145637 2019-03-29
Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)
Yonsei University
Phase 1 Completed
NCT02975141 2018-08-13
AFFECT
Ludwig-Maximilians - University of Munich
Phase 1 Unknown
NCT02216617 2017-10-27
TAPIS
Groupe Oncologie Radiotherapie Tete et Cou
Phase 1 Completed
NCT01721525 2017-10-25
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT01836341 2013-12-19
Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn